Key points are not available for this paper at this time.
Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Kelly et al. (Wed,) studied this question.
www.synapsesocial.com/papers/699562fba5dc7482368983be — DOI: https://doi.org/10.1056/nejmoa2032125
Ronan J. Kelly
Jaffer A. Ajani
Jarosław Kużdżał
Capital humano: revista para la integración y desarrollo de los recursos humanos
New England Journal of Medicine
Johns Hopkins University
University of California, San Francisco
Inserm
Building similarity graph...
Analyzing shared references across papers
Loading...